Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 7/20 | 0.39 |
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88961 | 0.96 | ALDH1A1 (0.48) | ALDH1A1KDM4EAHRGAACYP1A2 | |
| SCHEMBL1911330 | 0.91 | ALDH1A1 (0.42) | ALDH1A1KDM4EAHRGAAMAPK1 | |
| SCHEMBL88985 | 0.90 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAACYP1A2CYP2D6 | |
| SCHEMBL13490781 | 0.86 | AHR (0.41) | ALDH1A1KDM4EAHRMAPTHPGD | |
| SCHEMBL90334 | 0.84 | CNR1 (0.40) | ALDH1A1AHRCYP1A2CYP2D6MAPK1 | |
| SCHEMBL3075017 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4EAHRCYP1A2CYP2D6 | |
| SCHEMBL89284 | 0.84 | ALDH1A1 (0.39) | ALDH1A1AHRCYP1A2CYP2D6MAPK1 | |
| SCHEMBL8237574 | 0.84 | ALDH1A1 (0.39) | ALDH1A1KDM4EAHRCYP1A2CYP2D6 | |
| SCHEMBL8264192 | 0.84 | MAOB (0.41) | ALDH1A1AHRCYP1A2CYP2D6MAPK1 | |
| SCHEMBL13490763 | 0.84 | MAPT (0.46) | ALDH1A1KDM4EGAACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129538-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | NOVARTIS AG (CH) | 2010-06-24 | — | — | US | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006094763-A1 | 3,4,5-SUBSTITUTED PIPERIDINE COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | ALDH1A1 412/4885KDM4E 1290/4885AHR 1704/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | ALDH1A1 38/4885KDM4E 1650/4885AHR 3178/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | ALDH1A1 21/4885KDM4E 1140/4885AHR 3514/4885 |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | ALDH1A1 127/4885KDM4E 3004/4885AHR 2412/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | ALDH1A1 36/4885KDM4E 2265/4885AHR 3785/4885 |
| US-20100160305-A1 | 3, 4, 5 - Substituted Piperidine Compounds | REN, ACE, PIGO | ALDH1A1 56/4885KDM4E 1011/4885AHR 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.